Early Trial Data Show KRAS-Targeting Pill Extends Pancreatic Cancer Survival
Early trial results released in late April 2026 show experimental pill daraxonrasib roughly doubled median overall survival for pancreatic cancer patients versus standard chemotherapy in an early-stage clinical trial.[1]
Patients on daraxonrasib had median overall survival of 13.2 months versus 6.7 months for those on standard chemotherapy.[1] Among 26 pancreatic ductal adenocarcinoma patients with KRAS G12 mutations, more than one-third had at least 30 percent tumor reduction on CT scans.[1] In that subgroup, median survival was 13.1 months and progression-free survival was 8.5 months.[1]
Daraxonrasib blocks mutant KRAS, alterations that are found in more than 90 percent of common pancreatic cancers and in many colorectal and lung tumors.[1] Researchers cautioned the data are early and need confirmation in larger trials.[1] Roughly 30 percent of patients experienced severe side effects; earlier phases reported rashes in about 90 percent and diarrhea or gastrointestinal inflammation in roughly half.[1]
If confirmed, daraxonrasib could change treatment options for a tumor type that has long been deadly and hard to treat.[1]
Show source details & analysis (1 source)
📌 Key Facts
- Initial trial results released in late April 2026 showed daraxonrasib patients had median overall survival of 13.2 months versus 6.7 months on standard chemotherapy.
- Among 26 pancreatic ductal adenocarcinoma patients with KRAS G12 mutations, over one-third had at least a 30% tumor reduction on CT scans.
- In that KRAS G12 PDAC subgroup, median survival was 13.1 months with 8.5 months of progression-free survival.
- Roughly 30% of patients experienced severe side effects; earlier trial phases saw rashes in 90% of patients and diarrhea or GI inflammation in about half.
- KRAS mutations targeted by daraxonrasib occur in more than 90% of common pancreatic cancers, 40–45% of colorectal cancers, and up to 30% of non-small cell lung cancers.
📰 Source Timeline (1)
Follow how coverage of this story developed over time